LPCN Lipocine Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: LPCN

Price (delayed)

$2.2

Market cap

$18.14M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.96

Enterprise value

$13.12M

Sign up for free to view scoring metrics ?
Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 22

Lipocine Inc. is a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders using its proprietary drug delivery technologies. Lipocine's clinical development pipeline includes: TLANDO, LPCN 1144, TLANDO XR, LPCN ...

Highlights
Lipocine's equity has surged by 58% QoQ and by 19% YoY
The quick ratio has soared by 55% from the previous quarter but it has decreased by 35% YoY
LPCN's net income has shrunk by 113% YoY and by 19% QoQ
Lipocine's EPS has shrunk by 96% YoY and by 11% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: https://www.lipocine.com/
Peers: JAZZ CORT MDWD TBPH

Key stats

What are the main financial stats of LPCN

LPCN stock price

How has the Lipocine stock price performed over time
Intraday
0.46%
1 week
-2.65%
1 month
-3.93%
1 year
-31.25%
YTD
-72.6%
QTD
-72.47%

Financial performance

How have Lipocine's revenue and profit performed over time
Revenue
$2M
Gross profit
$2M
Operating income
-$12.13M
Net income
-$11.43M
Gross margin
100%
Net margin
-571.1%
LPCN's net income has shrunk by 113% YoY and by 19% QoQ
The company's operating income has shrunk by 88% YoY and by 17% QoQ
The gross profit has declined by 46% year-on-year
LPCN's revenue is down by 46% year-on-year

Price vs fundamentals

How does LPCN's price correlate with its fundamentals

Growth

What is Lipocine's growth rate over time

Valuation

What is Lipocine stock price valuation
P/E
N/A
P/B
0.7
P/S
7.47
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
6.55
Lipocine's EPS has shrunk by 96% YoY and by 11% QoQ
The P/B is 63% less than the last 4 quarters average of 1.9 and 56% less than the 5-year quarterly average of 1.6
Lipocine's equity has surged by 58% QoQ and by 19% YoY
The price to sales (P/S) is 95% lower than the 5-year quarterly average of 144.3 and 48% lower than the last 4 quarters average of 14.2
LPCN's revenue is down by 46% year-on-year

Efficiency

How efficient is Lipocine business performance
The ROIC has plunged by 172% YoY and by 14% from the previous quarter
Lipocine's ROE has plunged by 150% YoY and by 12% from the previous quarter
LPCN's ROA has dropped by 140% year-on-year and by 11% since the previous quarter
Lipocine's return on sales has decreased by 17% QoQ

Dividends

What is LPCN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for LPCN.

Financial health

How did Lipocine financials performed over time
LPCN's total liabilities has surged by 95% year-on-year
The quick ratio has soared by 55% from the previous quarter but it has decreased by 35% YoY
LPCN's debt is 100% smaller than its equity
Lipocine's equity has surged by 58% QoQ and by 19% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.